BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
BridgeBio (Nasdaq: BBIO) will report its fourth quarter and full year 2025 financial results and provide a business update after market close on February 24, 2026.
Rhea-AI Summary
BridgeBio (Nasdaq: BBIO) will report its fourth quarter and full year 2025 financial results and provide a business update after market close on February 24, 2026. The company will host a conference call and live webcast at 4:30 pm ET the same day. A replay will be available on the investor website for 30 days.
Details
News Market Reaction – BBIO
On Feb 17, the day this news came out, BBIO closed 0.80% above the previous close.
Data tracked by StockTitan Argus for the Feb 17 session.
Key Figures
- Earnings call date
- February 24, 2026
- Scheduled Q4 and full-year 2025 results release
- Earnings call time
- 4:30 pm ET
- Conference call and webcast start time
- Replay availability
- 30 days
- Webcast replay period on company website
Historical Context
-
Positive Phase 3 PROPEL 3 topline results in achondroplasia.
-
Nasdaq Rule 5635(c)(4) inducement RSU grants to new employees.
-
Additional RSU inducement awards under 2019 Inducement Equity Plan.
-
Pricing of $550M 0.75% convertible notes due 2033 to manage 2027 notes.
-
Proposed $550M convertible notes offering and share repurchase plan.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its fourth quarter and full year 2025 financial results and business updates after the market closes on Tuesday, February 24, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.
To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentations/. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
Participants may access the webcast by registering online using the following link, here.
About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.